# Olympia Pharmaceuticals

> Source: https://peptidewellnessusa.com/professionals/compounding-pharmacies/olympia/

An Orlando-based dual 503A/503B compounder with a peptide, hormone, weight-management, and IV catalog, licensed in 49 states.

Olympia runs both an FDA-registered 503B outsourcing facility and an affiliated 503A pharmacy (“Olympia Pharmacy”) out of Orlando — so, like Empower and Belmar, it can serve both office-use batches and patient-specific prescriptions.

## Facility & accreditation

Olympia appears on the FDA Registered Outsourcing Facilities (503B) list as “Olympia Pharmaceuticals, Orlando, FL” (initial registration March 10, 2014; most recent November 20, 2025) [1], and describes itself as an FDA-registered 503B outsourcing facility plus a 503A compounding pharmacy [2]. Its site shows a LegitScript certification and an NABP badge [2]. LegitScript’s own lookup lists olympiapharmacy.com as Certified, website type Pharmacy [5]. We did not confirm the NABP badge with NABP, and a direct search of ACHC’s PCAB directory returned no PCAB accreditation for the Orlando pharmacy [4] (the “Olympia” entries there are unrelated home-health organizations). The company says it is licensed in 49 states (all except California) [2].

## What they compound

Relevant lines: a dedicated peptides category, weight management, hormones (BHRT/TRT), IV nutrition, sexual health (including TriMix), dermatology, and other injectables [2]. Named compounded GLP-1 (semaglutide/tirzepatide) listings were not confirmed from the pages we reviewed.

## Regulatory record

As of our July 2026 read of the FDA 503B list, Olympia’s most recent inspection had run July 28–August 8, 2025 and resulted in a Form 483; recall status is “No,” and the action based on the last inspection is “Open,” with an FDA flag indicating a prior compounding-related action in its history [1]. The Form 483 (issued August 12, 2025) lists three observations centered on aseptic-process validation, written production/process-control procedures, and cleaning/disinfection practices in aseptic areas [3]. A Form 483 records inspection observations, not a final finding of violation; no warning letter or recall is listed in the current table. Dated to our review; status can change.

FDA inspected the Orlando outsourcing facility again from August 20 to September 3, 2026 and issued a second Form 483 on September 3, 2026, with eight observations [6]. They cover environmental monitoring in the aseptic processing areas, procedures to prevent microbial contamination of sterile products, production and process-control procedures, a stability program without reliable test methods (it names the beyond-use date the firm assigns to its sermorelin acetate 0.9 mg/mL injection), separation of aseptic operations, component testing, and second-person checks when components are added to a batch. As with the 2025 document, these are an investigator’s observations, not a final FDA finding. FDA’s compounding-actions list shows no warning letter, and its Enforcement Report no recall, for Olympia as of October 28, 2026.

## The read

A long-established dual-status compounder (503B since 2014) with a broad peptide/HRT/weight/IV catalog and near-national licensure. Form 483s from two consecutive inspections (2025 and 2026) and the prior-action flag are the items to watch — normal to track for a facility of this age and scale, but worth noting alongside the newer entrants.

## References

1. [FDA — Registered Outsourcing Facilities (503B) list.](https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities) (accessed 2026-07-01)
2. [Olympia Pharmaceuticals / Olympia Pharmacy — official site.](https://www.olympiapharmacy.com/) (accessed 2026-07-01)
3. [FDA — Form 483, Olympia Pharmaceuticals (issued 2025-08-12).](https://www.fda.gov/media/188647/download) (accessed 2026-07-01)
4. [ACHC / PCAB accredited-organization directory (searched “Olympia”).](https://organization.achc.org/) (accessed 2026-10-27)
5. [LegitScript — website certification status, olympiapharmacy.com: Certified.](https://www.legitscript.com/websites/?checker_keywords=olympiapharmacy.com) (accessed 2026-10-27)
6. [FDA — Form 483, OPS International Inc dba Olympia Pharmaceuticals, Orlando, FL (issued 2026-09-03).](https://www.fda.gov/media/195123/download) (accessed 2026-10-28)